Suppr超能文献

EVT 201 治疗老年原发性失眠患者可改善入睡、睡眠维持和日间嗜睡。

Treatment of elderly primary insomnia patients with EVT 201 improves sleep initiation, sleep maintenance, and daytime sleepiness.

机构信息

Sleep Medicine and Research Center, St. Luke's Hospital, 232 S. Woods Mill Road, Chesterfield, MO 63017, United States.

出版信息

Sleep Med. 2010 Jan;11(1):23-30. doi: 10.1016/j.sleep.2009.07.012. Epub 2009 Nov 28.

Abstract

OBJECTIVE

Two doses of EVT 201, a partial positive allosteric modulator of the GABA(A) system, were evaluated in elderly primary insomnia patients with daytime sleepiness.

PATIENTS AND METHODS

Participants were 149 elderly patients with DSM-IV primary insomnia including evidence of daytime sleepiness (53 males, 96 females; mean age 71.3yrs, range 65-86yrs). A randomized, multicentre, double-blind, placebo-controlled, parallel-group design was used to assess the hypnotic efficacy of EVT 201 1.5 and 2.5mg during seven consecutive nights. Polysomnography (PSG) was performed on nights 1, 6 and 7 of treatment. Daytime assessments on Day 8 included the multiple sleep latency test (MSLT), Rey Auditory Verbal Learning Test (RAVLT), Psychomotor Vigilance Task (PVT) and the Karolinska Sleepiness Scale (KSS). The primary endpoint was total sleep time (TST) and the key secondary endpoint was mean MSLT latency.

RESULTS

Compared to placebo, EVT 201 1.5 and 2.5mg increased TST (30.9, 56.4min, respectively; p=0.0001, p<0.0001); reduced wake after sleep onset (WASO; -15.2, -36.1min, respectively; p=0.014, p<0.0001); reduced latency to persistent sleep (LPS; -15.9, -19.9min, respectively; p=0.009, p=0.001). The 2.5mg dose also reduced WASO in hours 5-8 (-16.3min, p=0.001). Both doses also improved subjective sleep quality and usual subjective efficacy measures. A significantly longer mean MSLT latency was observed on Day 8 with both doses, compared to placebo (2min increase; p=0.03, both doses). The PVT, RAVLT, and POMS did not differ among treatment groups. No serious or unexpected treatment emergent adverse events were noted.

CONCLUSION

EVT 201 improved PSG measures of sleep onset and sleep maintenance and significantly reduced daytime physiological sleep tendency. These findings suggest that treatment of primary insomnia in older patients has the potential to improve daytime sleepiness as well as sleep.

摘要

目的

评估 EVT 201 的两种剂量(GABA(A) 系统部分正变构调节剂)对伴有日间嗜睡的老年原发性失眠患者的疗效。

方法

共有 149 名符合 DSM-IV 原发性失眠标准且伴有日间嗜睡(53 名男性,96 名女性;平均年龄 71.3 岁,范围 65-86 岁)的老年患者参与了这项研究。采用随机、多中心、双盲、安慰剂对照、平行组设计,评估 EVT 201 1.5mg 和 2.5mg 在连续 7 晚的催眠效果。在治疗的第 1、6 和 7 晚进行多导睡眠图(PSG)检测。第 8 天的日间评估包括多次睡眠潜伏期试验(MSLT)、 Rey 听觉言语学习测验(RAVLT)、精神运动警觉任务(PVT)和 Karolinska 嗜睡量表(KSS)。主要终点为总睡眠时间(TST),关键次要终点为平均 MSLT 潜伏期。

结果

与安慰剂相比,EVT 201 1.5mg 和 2.5mg 分别增加了 TST(分别增加 30.9、56.4 分钟;p=0.0001,p<0.0001);减少了睡眠潜伏期后觉醒(WASO;分别减少 15.2、36.1 分钟;p=0.014,p<0.0001);减少了潜伏期持续睡眠(LPS;分别减少 15.9、19.9 分钟;p=0.009,p=0.001)。2.5mg 剂量还减少了第 5-8 小时的 WASO(减少 16.3 分钟,p=0.001)。与安慰剂相比,两种剂量均显著改善了主观睡眠质量和常用的主观疗效指标。与安慰剂相比,两种剂量在第 8 天的平均 MSLT 潜伏期均显著延长(增加 2 分钟;p=0.03,两种剂量)。在治疗组之间,PVT、RAVLT 和 POMS 没有差异。没有出现严重或意外的治疗相关不良事件。

结论

EVT 201 改善了睡眠起始和睡眠维持的 PSG 指标,显著降低了日间生理睡眠倾向。这些发现表明,治疗老年原发性失眠有可能改善日间嗜睡和睡眠。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验